Quinupristin/dalfopristin

Seminars in Pediatric Infectious Diseases

Volumn 12, Issue 3, 2001, Pages 200-210

  Harrison, Christopher J ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG INDICATION; ENTEROCOCCUS FAECIUM; HUMAN; HYPERBILIRUBINEMIA; INFLAMMATION; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NAUSEA AND VOMITING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; URINARY TRACT INFECTION;

EID: 0034940177     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2001.24095     Document Type: Article

References (49)

1. The penicillins
2. Quinupristin/dalfopristin: A treatment option for vancomycin-resistant Enterococci
3. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
4. Chemotherapy for gram-positive nosocomial sepsis
5. Mechanisms of fluoroquinolone resistance: An update 1994-1998
6. Plasmid-mediated coresistance to streptogramins and vancomycin in Enterococcus faecium HM1032
7. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance
8. The bacterial outer membrane as a drug barrier
9. Antibiotic resistance in Streptococcus pneumoniae
10. Drug efflux as a mechanism of resistance
11. New faces of an old pathogen: Emergence and spread of multidrug-resistant Streptococcus pneumoniae
12. Streptogramins: An answer to antibiotic resistance in gram-positive bacteria
13. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium
14. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci
15. Antibiotic resistance in gram-positive bacteria: Epidemiological aspects
16. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study
17. Quinupristin/dalfopristin
18. Quinupristin/dalfopristin (Synercid) drug monograph
19. Efficacy and safety of treatment of pediatric patients with quinupristin/dalfopristin
20. Synergistic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium
21. Inhibition of protein synthesis by streptogramins and related antibiotics
22. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents
23. Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe
24. Quinupristin/dalfopristin-resistance enterococci of the satA (vatD) and satG (vatE) genotypes from different ecological origins in Germany
25. Local surveillance of antimicrobial resistance
26. Provisional interpretive criteria for quinpristin/dalfopristin susceptibility tests
27. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin
28. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program
29. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans
30. Pharmacodynamics of macrolides, azalides, and streptogramins: Effect on extracellular pathogens
31. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients
32. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model
33. Optimal treatment of complicated skin and skin structure infections
34. Treatment of hospitalised patients with complicated gram-positive skin and skin structure infections: Two randomised, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin
35. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: A synergistic drug combination
36. Quinupristin/dalfopristin: Therapeutic potential for vancomycin-resistant enterococcal infections
37. The efficacy and safety of quinupristin/dalfopeistin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
38. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium
39. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin
40. Safety and tolerability of quinupristin/dalfopristin: Administration guidelines
41. Interaction between quinupristin/dalfopristin and cyclosporine
42. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort
43. Prospective, randomized doseranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in treatment of catheter-related staphylococcal bacteremia
44. Occurrence and epidemiology of resistance to virginiamycin and streptogramins
45. Quinupristin/dalfopristin: A novel selective-spectrum antibiotic for treatment of multi-resistant and other gram-positive bacteria
46. Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods
47. Current and future management of infections due to methicillin-resistant staphylococci infections: The role of quinupristin/dalfopristin
48. In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae
49. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus